Molecular Predictors of Prevention of Recurrence in HCC With Sorafenib as Adjuvant Treatment and Prognostic Factors in the Phase 3 STORM Trial
Gut - United Kingdom
doi 10.1136/gutjnl-2018-316408
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 2, 2018
Authors
Publisher
BMJ